Cargando…
Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study
PURPOSE: To report the initial experience of managing treatment-resistant and treatment-naïve eyes with polypoidal choroidal vasculopathy (PCV) by using brolucizumab 6 mg. METHODS: This was a retrospective multicentric series of all consecutive eyes with PCV treated with brolucizumab. Treatment resi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240502/ https://www.ncbi.nlm.nih.gov/pubmed/35326038 http://dx.doi.org/10.4103/ijo.IJO_2513_21 |
_version_ | 1784737573907726336 |
---|---|
author | Chakraborty, Debdulal Maiti, Aniruddha Sengupta, Sabyasachi Mondal, Soumen Nandi, Krishnendu Chakraborty, Somnath |
author_facet | Chakraborty, Debdulal Maiti, Aniruddha Sengupta, Sabyasachi Mondal, Soumen Nandi, Krishnendu Chakraborty, Somnath |
author_sort | Chakraborty, Debdulal |
collection | PubMed |
description | PURPOSE: To report the initial experience of managing treatment-resistant and treatment-naïve eyes with polypoidal choroidal vasculopathy (PCV) by using brolucizumab 6 mg. METHODS: This was a retrospective multicentric series of all consecutive eyes with PCV treated with brolucizumab. Treatment resistance was defined as taking at least six prior anti-VEGF injections over the past 1 year and showing persistent disease activity in the form of intra (IRF) or subretinal fluid (SRF) or both. All patients were treated on a pro re nata (PRN) basis and followed up monthly. Retreatment was considered when either SRF or IRF were present at any time point during the study. RESULTS: We included 21 eyes of 21 patients with PCV with a mean age of 65.1 ± 9.9 years, of which 16 eyes (76%) were treatment-resistant. The mean follow-up period from receiving the first brolucizumab was 27.3 ± 3.3 weeks. Of the 21 eyes, seven eyes (33%) received three injections during follow-up, 13 eyes (62%) received two injections, and one eye received one injection. The mean injection-free interval was 12 ± 1.2 weeks. The median pretreatment vision was 0.6 logMAR (IQR = 0.47–1 logMAR) and improved to 0.3 logMAR (IQR = 0.25–0.6 logMAR), whereas the mean macular thickness improved from 443 ± 60 mm at baseline to 289 ± 25 mm (P < 0.001) at the last follow-up period. None of the eyes experienced any intraocular inflammation across 48 injection sessions CONCLUSION: Brolucizumab is safe and effective in controlling PCV disease in both treatment-resistant and treatment-naïve eyes. |
format | Online Article Text |
id | pubmed-9240502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-92405022022-06-30 Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study Chakraborty, Debdulal Maiti, Aniruddha Sengupta, Sabyasachi Mondal, Soumen Nandi, Krishnendu Chakraborty, Somnath Indian J Ophthalmol Special Focus, Retina, Original Article PURPOSE: To report the initial experience of managing treatment-resistant and treatment-naïve eyes with polypoidal choroidal vasculopathy (PCV) by using brolucizumab 6 mg. METHODS: This was a retrospective multicentric series of all consecutive eyes with PCV treated with brolucizumab. Treatment resistance was defined as taking at least six prior anti-VEGF injections over the past 1 year and showing persistent disease activity in the form of intra (IRF) or subretinal fluid (SRF) or both. All patients were treated on a pro re nata (PRN) basis and followed up monthly. Retreatment was considered when either SRF or IRF were present at any time point during the study. RESULTS: We included 21 eyes of 21 patients with PCV with a mean age of 65.1 ± 9.9 years, of which 16 eyes (76%) were treatment-resistant. The mean follow-up period from receiving the first brolucizumab was 27.3 ± 3.3 weeks. Of the 21 eyes, seven eyes (33%) received three injections during follow-up, 13 eyes (62%) received two injections, and one eye received one injection. The mean injection-free interval was 12 ± 1.2 weeks. The median pretreatment vision was 0.6 logMAR (IQR = 0.47–1 logMAR) and improved to 0.3 logMAR (IQR = 0.25–0.6 logMAR), whereas the mean macular thickness improved from 443 ± 60 mm at baseline to 289 ± 25 mm (P < 0.001) at the last follow-up period. None of the eyes experienced any intraocular inflammation across 48 injection sessions CONCLUSION: Brolucizumab is safe and effective in controlling PCV disease in both treatment-resistant and treatment-naïve eyes. Wolters Kluwer - Medknow 2022-04 2022-03-22 /pmc/articles/PMC9240502/ /pubmed/35326038 http://dx.doi.org/10.4103/ijo.IJO_2513_21 Text en Copyright: © 2022 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Special Focus, Retina, Original Article Chakraborty, Debdulal Maiti, Aniruddha Sengupta, Sabyasachi Mondal, Soumen Nandi, Krishnendu Chakraborty, Somnath Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study |
title | Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study |
title_full | Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study |
title_fullStr | Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study |
title_full_unstemmed | Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study |
title_short | Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study |
title_sort | initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in indian eyes – a multicenter retrospective study |
topic | Special Focus, Retina, Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240502/ https://www.ncbi.nlm.nih.gov/pubmed/35326038 http://dx.doi.org/10.4103/ijo.IJO_2513_21 |
work_keys_str_mv | AT chakrabortydebdulal initialexperienceintreatingpolypoidalchoroidalvasculopathywithbrolucizumabinindianeyesamulticenterretrospectivestudy AT maitianiruddha initialexperienceintreatingpolypoidalchoroidalvasculopathywithbrolucizumabinindianeyesamulticenterretrospectivestudy AT senguptasabyasachi initialexperienceintreatingpolypoidalchoroidalvasculopathywithbrolucizumabinindianeyesamulticenterretrospectivestudy AT mondalsoumen initialexperienceintreatingpolypoidalchoroidalvasculopathywithbrolucizumabinindianeyesamulticenterretrospectivestudy AT nandikrishnendu initialexperienceintreatingpolypoidalchoroidalvasculopathywithbrolucizumabinindianeyesamulticenterretrospectivestudy AT chakrabortysomnath initialexperienceintreatingpolypoidalchoroidalvasculopathywithbrolucizumabinindianeyesamulticenterretrospectivestudy |